DNTH
Price
$33.56
Change
+$0.64 (+1.94%)
Updated
Oct 27, 04:59 PM (EDT)
Capitalization
1.31B
Intraday Buy/Sell Signals
EYPT
Price
$12.12
Change
+$0.13 (+1.09%)
Updated
Oct 27, 04:59 PM (EDT)
Capitalization
967.42M
2 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

DNTH vs EYPT

Header iconDNTH vs EYPT Comparison
Open Charts DNTH vs EYPTBanner chart's image
Dianthus Therapeutics
Price$33.56
Change+$0.64 (+1.94%)
Volume$11.83K
Capitalization1.31B
EyePoint Pharmaceuticals
Price$12.12
Change+$0.13 (+1.09%)
Volume$23.44K
Capitalization967.42M
DNTH vs EYPT Comparison Chart in %
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. EYPT commentary
Oct 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 27, 2025
Stock price -- (DNTH: $32.92 vs. EYPT: $11.98)
Brand notoriety: DNTH and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 99% vs. EYPT: 99%
Market capitalization -- DNTH: $1.31B vs. EYPT: $967.42M
DNTH [@Biotechnology] is valued at $1.31B. EYPT’s [@Biotechnology] market capitalization is $967.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 1 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • DNTH’s FA Score: 1 green, 4 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, DNTH is a better buy in the long-term than EYPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 4 bearish.
  • EYPT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than EYPT.

Price Growth

DNTH (@Biotechnology) experienced а -7.66% price change this week, while EYPT (@Biotechnology) price change was +3.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.61%. For the same industry, the average monthly price growth was +11.19%, and the average quarterly price growth was +64.92%.

Reported Earning Dates

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (-0.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($1.31B) has a higher market cap than EYPT($967M). EYPT YTD gains are higher at: 60.805 vs. DNTH (51.009). DNTH has higher annual earnings (EBITDA): -129.49M vs. EYPT (-172.05M). DNTH (257M) and EYPT (256M) have equal amount of cash in the bank . DNTH has less debt than EYPT: DNTH (1.33M) vs EYPT (21.8M). EYPT has higher revenues than DNTH: EYPT (51.9M) vs DNTH (4.85M).
DNTHEYPTDNTH / EYPT
Capitalization1.31B967M136%
EBITDA-129.49M-172.05M75%
Gain YTD51.00960.80584%
P/E Ratio3.24N/A-
Revenue4.85M51.9M9%
Total Cash257M256M100%
Total Debt1.33M21.8M6%
FUNDAMENTALS RATINGS
DNTH vs EYPT: Fundamental Ratings
DNTH
EYPT
OUTLOOK RATING
1..100
5867
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
3179
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4244
P/E GROWTH RATING
1..100
6315
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (59) in the null industry is in the same range as EYPT (68) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to EYPT’s over the last 12 months.

DNTH's Profit vs Risk Rating (31) in the null industry is somewhat better than the same rating for EYPT (79) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew somewhat faster than EYPT’s over the last 12 months.

DNTH's SMR Rating (97) in the null industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to EYPT’s over the last 12 months.

DNTH's Price Growth Rating (42) in the null industry is in the same range as EYPT (44) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for DNTH (63) in the null industry. This means that EYPT’s stock grew somewhat faster than DNTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHEYPT
RSI
ODDS (%)
Bearish Trend 4 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 7 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
75%
Aroon
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWHUX36.980.41
+1.12%
Nationwide Bailard Tech & Sci Instl Svc
ACFNX86.010.72
+0.84%
American Century Focused Dynamic Gr R6
SMVSX29.320.24
+0.83%
Invesco Small Cap Value R6
CVLFX15.540.06
+0.39%
Cullen Value C
EQNBX23.860.09
+0.38%
MFS Equity Income B

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with OCUL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-1.05%
OCUL - DNTH
47%
Loosely correlated
+0.44%
EYPT - DNTH
45%
Loosely correlated
+4.17%
CGON - DNTH
45%
Loosely correlated
+4.03%
XNCR - DNTH
44%
Loosely correlated
+7.05%
SYRE - DNTH
44%
Loosely correlated
+4.47%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+4.17%
OCUL - EYPT
60%
Loosely correlated
+0.44%
LYRA - EYPT
58%
Loosely correlated
+1.43%
ATHE - EYPT
54%
Loosely correlated
-1.30%
BEAM - EYPT
50%
Loosely correlated
-0.85%
IDYA - EYPT
48%
Loosely correlated
+2.67%
More